Follicular Lymphoma
News
FDA issues CRL for proposed biosimilar rituximab
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed...
News
FDA approves CAR T-cell therapy for lymphoma
The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah®) for its second indication. The chimeric antigen receptor (CAR)...
News
Team identifies 5 subtypes of DLBCL
New research has revealed 5 genetic subtypes of diffuse large B-cell lymphoma (DLBCL). Researchers identified a group of low-risk activated B-cell...
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
Conference Coverage
Inhibitor outperforms rivals in leukemia, lymphoma
CHICAGO—Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain...
From the Journals
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
News from the FDA/CDC
FDA grants priority review of follicular lymphoma drug
The target date for FDA action is Oct. 5, 2018.
News
Tazemetostat exhibits antitumor activity in phase 1 trial
The EZH2 inhibitor tazemetostat demonstrated a “favorable safety profile and antitumor activity” in a phase 1 study, according to researchers. The...
News
Duvelisib NDA granted priority review
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for duvelisib, a dual PI3K delta/gamma...
From the Journals
Experimental voxtalisib shows mixed results in phase 2 study
The novel pan-P13K/mTOR inhibitor induced complete responses in some patients with follicular lymphoma, but not aggressive malignancies, including...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.